Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2/3 Study of Evorpacept (ALX148) in Patients With Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma (ASPEN-06)

Next Previous
Trial Profile

A Phase 2/3 Study of Evorpacept (ALX148) in Patients With Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma (ASPEN-06)

Status: Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 24 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Evorpacept (Primary) ; Paclitaxel; Ramucirumab; Trastuzumab
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Solid tumours
  • Focus Proof of concept; Registrational; Therapeutic Use
  • Acronyms ASPEN-06
  • Sponsors ALX Oncology

Most Recent Events

  • 30 Oct 2025 According to a ALX Oncology media release, company will be hosting a teleconference, which will include review of the upcoming data from this trial for presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, Friday, November 7, 2025 at 5:30 a.m. PT / 8:30 a.m. ET
  • 03 Oct 2025 According to a ALX Oncology media release, updated data from its Phase 2 ASPEN-06 trial will be presented during a poster session at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting taking place November 5-9, 2025, in National Harbor, Maryland.
  • 12 Jun 2025 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top